Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on September 4, 2025
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
GlobeNewswire
·
September 4, 2025
SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic …
Branded Legacy, Inc. Expands Capabilities with Acquisition of State-of-the-Art GMP Facility in Vancouver
GlobeNewswire
·
September 4, 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG), a pioneering biotechnology company dedicated to revolutionizing addiction treatment and harm reduction solutions, today announced that its …
BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE), a clinical-stage company advancing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that Jonathan Solomon, the Company’s …
Sofwave Receives FDA, Pre-market Clearance for Pure Impact VIPTM Standalone EMS Device For Comprehensive Multi-Body Area Muscle Strengthening and Firming
GlobeNewswire
·
September 4, 2025
The Pure Impact VIP™ standalone device represents a major extension of the Pure Impact™ product line and introduces an all-in-one independent unit Standalone device is launched with an enhanced Pure Impact™ feature set which provides comprehensive muscle …
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
GlobeNewswire
·
September 4, 2025
Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistance Additional poster presentations highlight SCY-247’s broad spectrum of …
Sen. Debbie Stabenow, State Legislators to Highlight Annual Walk a Mile in My Shoes Rally & Warn Against State PIHP Procurement Process
GlobeNewswire
·
September 4, 2025
LANSING, Mich., Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Community Mental Health Association of Michigan (CMHAM) announces that former U.S. Senator Debbie Stabenow is this year’s keynote speaker at the Walk a Mile in My Shoes Rally, which will begin at 1:30 …
Fifty1 Labs, Inc. Leadership Publishes Landmark Framework to Unlock Global Oncology Data Through AI-Driven Real-World Evidence
GlobeNewswire
·
September 4, 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN – Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), announces the publication of a landmark technical primer on "transportability" methods in oncology real-world evidence …
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
GlobeNewswire
·
September 4, 2025
Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic …
Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base
GlobeNewswire
·
September 4, 2025
Internationally recognized vascular surgeon, Dr. Koen Deloose provides patient access to latest innovative treatments and personalized care BERKELEY, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a …
CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with …
Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies
GlobeNewswire
·
September 4, 2025
Dr. Trieu’s prolific career includes multibillion-dollar drug discoveries targeting cancers of the breast, pancreas and non-small cell lung cancer, among others Oncotelic’s robust portfolio and clinical pipeline is supported by the innovations and …
TOMI Environmental Solutions to Present at the H.C. Wainwright Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
FREDERICK, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its …
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
GlobeNewswire
·
September 4, 2025
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance Preparations for dose-ranging Phase 2 study of NPM …
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
GlobeNewswire
·
September 4, 2025
THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of …
Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model
GlobeNewswire
·
September 4, 2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today announced compelling preclinical results for its investigational compound BMB‑201, in a validated isosorbide dinitrate (ISDN) rat model of vascular headache. …
Nuwellis Introduces New 24-Hour Aquadex™ Circuit to Support Hospital-Based Outpatient and Short-Term Fluid Management
GlobeNewswire
·
September 4, 2025
MINNEAPOLIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, announced plans to introduce a new 24-hour circuit for Aquadex therapy in the United States this fall. The new circuit is designed for single-day outpatient …
STRATA Skin Sciences’ Elevate 360 Consulting Offering Drives Growth in Partner Clinic Operations and Fuels New Partnership Agreements
GlobeNewswire
·
September 4, 2025
HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of …
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
GlobeNewswire
·
September 4, 2025
Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care STAAR study demonstrated …
IO Biotech Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
September 4, 2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that members of its senior management team …
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
GlobeNewswire
·
September 4, 2025
RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced …